Insider Buying: Geron (NASDAQ:GERN) EVP Buys $11,280.00 in Stock

Geron Corporation (NASDAQ:GERN – Get Free Report) EVP Timothy Williams bought 12,000 shares of Geron stock in a transaction that occurred on Monday, November 16th. The shares were acquired at an average price of $0.94 per share, for a total transaction of $11,280.00. Following the completion of the transaction, the executive vice president directly owned 12,000 shares of the company’s stock, valued at $11,280. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Geron Stock Down 0.9%

Shares of NASDAQ:GERN opened at $0.99 on Thursday. The stock’s 50-day moving average price is $1.15 and its two-hundred day moving average price is $1.40. The company has a current ratio of 6.31, a quick ratio of 4.61 and a debt-to-equity ratio of 0.53. Geron Corporation has a 12-month low of $0.84 and a 12-month high of $2.01. The firm has a market cap of $638.38 million, a price-to-earnings ratio of -12.39 and a beta of 0.62.

Institutional Trading of Geron

A number of hedge funds have recently made changes to their positions in GERN. Hsbc Holdings PLC acquired a new position in shares of Geron during the second quarter worth $25,000. LCM Capital Management Inc acquired a new stake in Geron during the 3rd quarter valued at $25,000. GTS Securities LLC grew its holdings in Geron by 71.6% during the 2nd quarter. GTS Securities LLC now owns 23,772 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 9,921 shares in the last quarter. M Holdings Securities Inc. acquired a new stake in Geron during the 3rd quarter valued at $34,000. Finally, OneDigital Investment Advisors LLC acquired a new stake in Geron during the 2nd quarter valued at $38,000. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on GERN shares. Needham & Company LLC decreased their target price on shares of Geron from $4.00 to $2.50 and set a “buy” rating on the stock in a research report on Wednesday, October 28th. Wedbush dropped their price target on shares of Geron to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, October 28th. Finally, Weiss Ratings raised shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 9th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Geron presently has a consensus rating of “Hold” and a consensus target price of $3.75.

Read Our Latest Analysis on Geron

About Geron

(Get Free Report)

Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.

Featured Articles

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.